J. B. Chemicals & Pharmaceuticals Limited
NSE: JBCHEPHARM BSE: JBCHEPHARM
NSE
1,658.70
12.40 (0.75%)
Prev Close
1646.3
Open Price
1660
Volume
100,079
Today Low / High
1650 / 1682.1
52 WK Low / High
1385.75 / 2030
Range
1,576 - 1,742
BSE
1,651.90
6.65 (0.40%)
Prev Close
1645.25
Open Price
1667.95
Volume
5,230
Today Low / High
1647.05 / 1680
52 WK Low / High
1303 / 2029
Range
1,569 - 1,734
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1658.7 (target range: 1,576 - 1,742), reflecting a change of 12.4 (0.7532%). On the BSE, it is listed at 1651.9 (target range: 1,569 - 1,734), showing a change of 6.65 (0.40419%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
1,660.00
-0.08%
17 Apr
1,643.00
0.20%
16 Apr
1,601.00
1.69%
15 Apr
1,585.90
0.35%
11 Apr
1,540.00
2.05%
09 Apr
1,522.50
1.31%
08 Apr
1,515.05
0.50%
07 Apr
1,401.15
8.33%
04 Apr
1,580.95
-3.26%
03 Apr
1,567.80
0.82%
02 Apr
1,564.90
0.12%
01 Apr
1,620.00
-4.30%
28 Mar
1,625.00
-0.11%
27 Mar
1,636.00
-1.24%
26 Mar
1,733.70
-1.44%
25 Mar
1,694.80
2.10%
24 Mar
1,650.30
1.78%
J. B. Chemicals & Pharmaceuticals Limited Graph
J. B. Chemicals & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for J. B. Chemicals & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,658.70, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,651.90 | 1,668.42 | 1,501.58 - 1,835.26 |
| 1,684.94 | 1,347.95 - 2,021.93 | ||
| 1,701.46 | 1,191.02 - 2,211.89 | ||
| Bearish Scenario | 1,651.90 | 1,635.38 | 1,471.84 - 1,798.92 |
| 1,618.86 | 1,295.09 - 1,942.63 | ||
| 1,602.34 | 1,121.64 - 2,083.05 |
Overview of J. B. Chemicals & Pharmaceuticals Limited
ISIN
INE572A01036
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
347,205
Market Cap
258,221,804,814
Last Dividend
15.25
Official Website
IPO Date
2002-07-01
DCF Diff
379.17
DCF
1,295
Financial Ratios Every Investor Needs
Stock Dividend of JBCHEPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-07 | February 07, 25 | 8.5 | 8.5 | 2025-02-08 | 2025-02-21 | |
| 2024-08-14 | August 14, 24 | 6.75 | 6.75 | 2024-08-14 | 2024-09-20 | |
| 2024-02-16 | February 16, 24 | 5.5 | 5.5 | 2024-02-16 | 2024-03-07 | |
| 2023-08-16 | August 16, 23 | 9.25 | 18.5 | 2023-08-17 | 2023-09-23 | |
| 2023-02-17 | February 17, 23 | 4.25 | 8.5 | 2023-02-18 | 2023-03-01 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3,447.67 Cr | 2,121.75 Cr | 1,325.92 Cr | 0.3846 | 30.56 Cr | 33.70 Cr | 754.16 Cr | 552.63 Cr | 35.66 | 933.48 Cr | 0.1603 |
| 2023-03-31 | 3,149.28 Cr | 384.22 Cr | 2,765.06 Cr | 0.8780 | 31.93 Cr | 547.04 Cr | 591.79 Cr | 409.84 Cr | 26.50 | 704.37 Cr | 0.1301 |
| 2022-03-31 | 2,424.24 Cr | 863.37 Cr | 1,560.87 Cr | 0.6439 | 29.11 Cr | 57.99 Cr | 473.90 Cr | 385.36 Cr | 24.93 | 581.53 Cr | 0.1590 |
| 2021-03-31 | 2,005.85 Cr | 717.44 Cr | 1,288.41 Cr | 0.6423 | 23.53 Cr | 7.88 Cr | 489.54 Cr | 447.96 Cr | 28.98 | 672.26 Cr | 0.2233 |
| 2020-03-31 | 1,742.70 Cr | 654.27 Cr | 1,088.44 Cr | 0.6246 | 19.39 Cr | 4.33 Cr | 318.22 Cr | 272.05 Cr | 17.10 | 418.35 Cr | 0.1561 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 88.22 Cr | 3,994.13 Cr | 1,070.80 Cr | 2,923.3300 Cr | 377.66 Cr | 289.44 Cr | 502.51 Cr | 634.88 Cr | 12.99 Cr | 1.70 Cr | 23.71 Cr | 868.2261 Cr |
| 2023-03-31 | 76.93 Cr | 3,553.87 Cr | 1,073.52 Cr | 2,480.3500 Cr | 572.45 Cr | 495.52 Cr | 430.49 Cr | 576.42 Cr | 118.25 Cr | 15.21 Cr | 13.78 Cr | 554.4500 Cr |
| 2022-03-31 | 56.54 Cr | 2,607.40 Cr | 468.79 Cr | 2,134.1230 Cr | 54.56 Cr | -1.99 Cr | 409.96 Cr | 566.82 Cr | 116.47 Cr | 3.17 Cr | 12.72 Cr | 383.7156 Cr |
| 2021-03-31 | 28.69 Cr | 2,238.12 Cr | 424.69 Cr | 1,809.7248 Cr | 44.99 Cr | 16.30 Cr | 347.45 Cr | 569.66 Cr | 108.56 Cr | 4.93 Cr | 12.91 Cr | 345.2737 Cr |
| 2020-03-31 | 29.01 Cr | 1,813.56 Cr | 375.57 Cr | 1,435.4893 Cr | 38.22 Cr | 9.21 Cr | 274.67 Cr | 584.20 Cr | 150.42 Cr | 5.97 Cr | 69.45 Cr | 312.8460 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 800.6117 Cr | -403.8304 Cr | -374.0799 Cr | 539.2447 Cr | 11.2807 Cr | 88.2151 Cr | -126.1128 Cr | 552.6278 Cr | -191.5957 Cr | -156.9875 Cr | -72.0300 Cr |
| 2023-03-31 | 625.6100 Cr | -961.7900 Cr | 356.5400 Cr | -139.3400 Cr | 20.3900 Cr | 76.9300 Cr | -764.9500 Cr | 555.2300 Cr | 523.1596 Cr | -127.5926 Cr | -20.5200 Cr |
| 2022-03-31 | 170.1345 Cr | 2.3199 Cr | -138.3851 Cr | -536.6547 Cr | 34.0703 Cr | 56.5441 Cr | -706.7892 Cr | 504.9020 Cr | -0.3273 Cr | -127.5628 Cr | -62.5143 Cr |
| 2021-03-31 | 314.7849 Cr | -230.6758 Cr | -87.4228 Cr | 267.0119 Cr | -3.2782 Cr | 22.4737 Cr | -47.7730 Cr | 596.8854 Cr | 0.3223 Cr | -73.2403 Cr | -70.0857 Cr |
| 2020-03-31 | 275.3717 Cr | 24.3027 Cr | -306.0513 Cr | 202.4040 Cr | -6.3897 Cr | 25.7519 Cr | -72.9677 Cr | 348.8923 Cr | 6.3140 Cr | -141.0031 Cr | -30.9120 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 963.49 Cr | 316.74 Cr | 646.75 Cr | 0.6713 | 212.57 Cr | 162.49 Cr | 10.46 | 262.51 Cr | 0.1686 |
| 2024-09-30 | 1,000.62 Cr | 550.87 Cr | 449.75 Cr | 0.4495 | 228.64 Cr | 174.57 Cr | 11.24 | 280.47 Cr | 0.1745 |
| 2024-06-30 | 1,004.40 Cr | 547.44 Cr | 456.96 Cr | 0.4550 | 239.59 Cr | 176.83 Cr | 11.39 | 286.26 Cr | 0.1761 |
| 2024-03-31 | 861.73 Cr | 493.72 Cr | 368.01 Cr | 0.4271 | 157.38 Cr | 126.16 Cr | 8.22 | 214.75 Cr | 0.1464 |
| 2023-12-31 | 844.51 Cr | 273.63 Cr | 570.88 Cr | 0.6760 | 196.44 Cr | 133.57 Cr | 8.62 | 230.47 Cr | 0.1582 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 89.89 Cr | 319.40 Cr | 416.86 Cr | 817.14 Cr | 543.67 Cr | 1,913.30 Cr | 641.67 Cr | 4,029.41 Cr | 817.18 Cr |
| 2024-03-31 | 95.54 Cr | 364.65 Cr | 460.19 Cr | 686.92 Cr | 502.51 Cr | 1,853.35 Cr | 634.88 Cr | 3,994.13 Cr | 1,070.80 Cr |
| 2023-12-31 | -393.29 Cr | 786.58 Cr | 393.29 Cr | 0.00 Cr | 0.00 Cr | 393.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 91.62 Cr | 354.44 Cr | 446.06 Cr | 714.70 Cr | 424.53 Cr | 1,757.95 Cr | 637.02 Cr | 3,799.20 Cr | 1,082.49 Cr |
| 2023-06-30 | -269.20 Cr | 538.41 Cr | 269.20 Cr | 0.00 Cr | 0.00 Cr | 269.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 176.83 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 126.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 133.57 Cr | 68.06 Cr | 0.00 Cr | 0.00 Cr | 68.06 Cr | 161.26 Cr | 93.20 Cr | 0.00 Cr | 68.06 Cr |
| 2023-09-30 | 150.59 Cr | 72.04 Cr | 0.00 Cr | 0.00 Cr | 72.04 Cr | 93.20 Cr | 21.16 Cr | 0.00 Cr | 72.04 Cr |
| 2023-06-30 | 142.32 Cr | 62.76 Cr | 0.00 Cr | 0.00 Cr | 62.76 Cr | 141.57 Cr | 78.81 Cr | 0.00 Cr | 62.76 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2023-09-18 | September 18, 23 | 2:1 |
| 2005-04-05 | April 05, 05 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Vice President of Finance & Accounts
Mr. Bhagwat Singh Deora
Gender: male
Year Born: 1982
Chief Executive Officer & Whole-Time Director
Mr. Nikhil Ashokkumar Chopra
Gender: male
Year Born: 1973
Chief Financial Officer
Mr. Narayan Saraf
Gender: male
Year Born: 1980
Vice President of HR & Administration
Mr. Sridhar Bharadwaj
Gender: male
Year Born: 1967
Vice President of Legal
Mr. Himanshu Ranvah
Gender: male
Year Born: 1985
Executive Vice President of Operations of Daman
Mr. Parmeshwar B. Bang
Gender: male
Year Born: 1968
Vice President of Information & Technology
Mr. Suresh Bhise
Gender: male
Year Born: 1966
Assistant Vice President Human Resource
Suresh Amin
Gender: Not Specified
Year Born:
President of Operations
Mr. Kunal Khanna
Gender: male
Year Born: 1980
President of Global Business
Mr. Pradeep Kumar Singh
Gender: male
Year Born: 1964
FAQs about J. B. Chemicals & Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mr. Nikhil Ashokkumar Chopra.
What is the current market price of the stock?
The current price is ₹1,658.70.
What is the 52-week price range?
The range is ₹1385.75-2030.
What is the market capitalization of the company?
The market capitalization is ₹25,822.18 crores.
What is the dividend yield?
The dividend yield is 0.92%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 40.26.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of J. B. Chemicals & Pharmaceuticals Limited (ISIN: INE572A01036) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹25,822.18 crores and an average daily volume of 347,205 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹15.25.